Vasculitis and Giant Cell Arteritis News

Patients with a history of recent respiratory, skin, urogenital and gastrointestinal tract infections demonstrate a two-fold increased risk for subsequent Kawasaki disease, according to data published in RMD Open.

The field of rheumatology is constantly in flux.

Reducing glucocorticoid use in the treatment of giant cell arteritis and polymyalgia rheumatica — due to the steroid’s host of related toxicities and adverse effects — has long been a goal for rheumatologists.

Nearly all children with ANCA-associated vasculitis demonstrate active kidney disease at diagnosis, and their renal function status is strongly predictive of outcomes 1 year later, according to data published in Arthritis & Rheumatology.

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

In this video, Rula Hajj-Ali, MD discusses her process for putting together a treatment plan for a vasculitis patient.

In this video, Rula Hajj-Ali, MD discusses her most important keys for vasculitis awareness.

In this video, Rula Hajj-Ali, MD discusses the state of the pipeline for developing vasculitis treatments.

In this video, Rula Hajj-Ali, MD details the major unmet needs in vasculitis treatment.